| Literature DB >> 26260341 |
Giorgia Botta1, Bruno Mattia Bizzarri1, Adriana Garozzo2, Rossella Timpanaro2, Benedetta Bisignano2, Donatella Amatore3, Anna Teresa Palamara3, Lucia Nencioni4, Raffaele Saladino5.
Abstract
Hydroxytyrosol and dihydrocaffeoyl catechols with lipophilic properties have been synthesized in high yield using tyrosinase immobilized on multi-walled carbon nanotubes by the Layer-by-Layer technique. All synthesized catechols were evaluated against a large panel of DNA and RNA viruses, including Poliovirus type 1, Echovirus type 9, Herpes simplex virus type 1 (HSV-1), Herpes simplex virus type 2 (HSV-2), Coxsackievirus type B3 (Cox B3), Adenovirus type 2 and type 5 and Cytomegalovirus (CMV). A significant antiviral activity was observed in the inhibition of HSV-1, HSV-2, Cox B3 and CMV. The mechanism of action of the most active dihydrocaffeoyl derivative was investigated against a model of HSV-1 infection.Entities:
Keywords: Antiviral activity; Catechols; DNA and RNA viruses; Dihydrocaffeoyl derivatives; Hydroxytyrosol derivatives
Mesh:
Substances:
Year: 2015 PMID: 26260341 PMCID: PMC7125559 DOI: 10.1016/j.bmc.2015.07.061
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641
Figure 1Preparation of MWCNT/Tyr. Step A: coating of Tyr and BSA on functionalized PDDA/MWCNTs. Step B: cross-linking with GA.
Kinetic parameters for native tyrosinase (Tyr) and catalyst MWCNT/Tyra
| Plot | ||||||
|---|---|---|---|---|---|---|
| Tyr | MWCNT/Tyr | Tyr | MWCNT/Tyr | Tyr | MWCNT/Tyr | |
| Lineweaver-Burk | 0.13 | 0.10 | 30 | 6 | 909 | 181 |
| Hanes | 0.11 | 0.15 | 27 | 14 | 818 | 424 |
| Eadie-Hofstee | 0.11 | 0.13 | 26 | 12 | 788 | 364 |
Kcat is defined as vmax (Δabsorbance per minute)/[Tyr] (micromoles per milliliter). All experiments were conducted in triplicate using free and immobilized tyrosinase. Average errors in kinetic parameters were 2–4% for Km and 1–3% for Vmax.
Scheme 1Oxidation of compounds 1 and 1a–d with MWCNT/Tyr.
Scheme 2Oxidation of compounds 2a–d with MWCNT/Tyr.
Synthesis of hydroxytyrosol and dihydrocaffeoyl catechol derivatives 3, 3a–d and 4a–da
| Entry | Substrate | Catalyst | Product | Conversion (%) | Yield (%) |
|---|---|---|---|---|---|
| 1 | Tyr | 98 | 98 | ||
| 2 | Tyr/ECM | 45 | 44 | ||
| 3 | MWCNT/Tyr | 98 | 98 | ||
| 4 | Tyr | 98 | 98 | ||
| 5 | Tyr/ECM | 47 | 46 | ||
| 6 | MWCNT/Tyr | 98 | 98 | ||
| 7 | MWCNT/Tyr | 98 | 98 | ||
| 8 | MWCNT/Tyr | 98 | 98 | ||
| 9 | MWCNT/Tyr | 98 | 98 | ||
| 10 | Tyr/ECM | 53 | 51 | ||
| 11 | MWCNT/Tyr | 98 | 98 | ||
| 12 | MWCNT/Tyr | 98 | 98 | ||
| 13 | MWCNT/Tyr | 98 | 98 | ||
| 14 | MWCNT/Tyr | 98 | 98 |
The oxidation was performed on 0.05 mmol of substrate with the appropriate catalyst (240 units) in CH2Cl2/buffer (Na phosphate 0.1 M pH 7, CH2Cl2/buffer ratio 1.0:0.1) at 25 °C under O2 atmosphere for 24 h.
In this case an higher amount of immobilized enzyme (600 units) was required to obtain a quantitative yield of desired product.
Reusability of MWCNT/Tyr and Tyr/ECM in the oxidation of 1a,b
| Entry | Run | Tyr/ECM (yield%) | MWCTN/Tyr (yield%) |
|---|---|---|---|
| 1 | 1 | 46 | 98 |
| 2 | 2 | 46 | 98 |
| 3 | 3 | 41 | 98 |
| 4 | 4 | 36 | 97 |
| 5 | 5 | 32 | 95 |
| 6 | 6 | 29 | 91 |
Reusability is expressed as the yield in% of catechol 3 obtained by oxidation of 1 with Tyr/ECM-LbL and MWCTN/Tyr.
The oxidation of 1 (0.05 mmol) was performed in the presence of the appropriate catalyst (240 units) in CH2Cl2/buffer (Na phosphate 0.1 M pH 7, CH2Cl2/buffer ratio 1.0:0.1) at 25 °C under O2 atmosphere for 24 h.
Antiviral activity of cathecol derivatives 3, 3a–d and 4a–d against different DNA and RNA viruses
| Compound | ID50 | |||||||
|---|---|---|---|---|---|---|---|---|
| Polio 1 | CoxB3 | ECHO9 | HSV-1 | HSV-2 | Adeno 2 | Adeno 5 | CMV | |
| >200 | >200 | >200 | >200 | ND | >200 | >200 | >200 | |
| >100 | >100 | >100 | >100 | >100 | >100 | >100 | 100 | |
| >75 | 20 | >75 | 15 | 60 | >40 | >40 | 40 | |
| >200 | >200 | >200 | >200 | ND | >200 | >200 | ND | |
| >200 | 100 | >200 | >200 | >200 | >200 | >200 | 25 | |
| >100 | 50 | >100 | 20 | 40 | >50 | >50 | >50 | |
| >40 | >40 | >40 | 20 | 40 | >40 | >40 | >40 | |
| >100 | >100 | >100 | >100 | 100 | >100 | >100 | >100 | |
| >25 | >25 | >25 | 25 | ND | >25 | >25 | >25 | |
Values are mean ± 0·5 SD (maximal SD estimated) for three separate assays.
ID50, concentration which inhibited virus plaque formation and virus-induced cytopathogenicity by 50%.
Cytotoxicity of cathecol derivatives 3, 3a–d and 4a–d
| Compound | CD50 | ||
|---|---|---|---|
| VERO | HEp2 | HFF1 | |
| >200 | >200 | >200 | |
| 100 | 100 | 100 | |
| 75 | 40 | 40 | |
| >200 | >200 | ND | |
| 200 | 200 | 100 | |
| 100 | 50 | 50 | |
| 40 | 40 | 40 | |
| 100 | 100 | 100 | |
| 25 | 25 | 25 | |
Values are mean ± 0·5 SD (maximal SD estimated) for three separate assays.
CD50, concentration which inhibited cells growth by 50% when compared with control culture.
Figure 2Effect of addition of compound 3b (5 × ID50) at various times during the replicative cycle of HSV-1. Time 0 = post 2 h adsorption period at 4 °C. The concentrations used are ratios with respect to the ID50 (e.g., 5× the ID50 is 5 times the ID50 of the compound). Each value represents the mean ± SEM of three separate assays.
Figure 3Effect of compound 3b (1×, 5× ID50) on the adsorption of HSV-1. Infective center assay data were plotted as percentage of virus infectivity relative to the no-drug control. The concentrations used are ratios with respect to the ID50.